ClinicalTrials.gg
Active, not recruitingNCT06777316Updated Apr 17, 2026

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

A Phase 1/2 interventional study of CGT4859 in Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma and Other Solid Tumors, Adult, sponsored by Cogent Biosciences, Inc.. Active, not recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Cogent Biosciences, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Planned enrollment
73rd of 279
110 · median 44
Started
2025
with 16 others
Phase 1/2
42 of 328
12 open now
Primary completion
2027-03
later than 33 of 108 live
Registered
293rd of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 73rd largest by planned enrollment of the 279 interventional ones that give a count, is one of 17 that started in 2025, is one of 42 in phase 1/2, reaches primary completion later than 33 of the 108 other live ones, and was the 293rd registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

03

Conditions studied

  • Intrahepatic Cholangiocarcinoma (Icc)
  • Cholangiocarcinoma
  • Other Solid Tumors, Adult
  • FGFR2 Gene Fusion/Rearrangement
  • FGFR2 Gene Amplification
  • FGFR2 Gene Short Variants
  • FGFR3 Gene Fusion/Rearrangement
  • FGFR3 Gene Amplification
  • FGFR3 Gene Short Variants
  • FGFR2 Genetic Alterations
  • FGFR3 Genetic Alterations
  • Advanced Solid Tumors

Keywords

  • Cholangiocarcinoma
  • Intrahepatic Cholangiocarcinoma
  • Advanced Solid Tumors
  • Investigational Drug
  • Phase 1
  • Phase 2
  • FGFR2
  • FGFR3
  • FGFR2/3
  • First in human
  • FGFR 2 genetic alterations
  • FGFR3 genetic alterations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed locally advanced, , and/or unresectable iCCA or other solid tumor with documented FGFR2/3 alteration in blood and/or tumor.
  2. Previously treated with, not appropriate for, or declined standard-of-care treatment.
  3. Have per v1.1.
  4. (ECOG) performance status of 0-1.
  5. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits.
  6. Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), including resolution of laboratory abnormalities, before the first dose of study drug. Exceptions are alopecia, hypothyroidism, or type 1 diabetes mellitus controlled with medical intervention, and paronychia controlled with local intervention.

Key Exclusion Criteria:

  1. Received chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug.
  2. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug.
  3. Clinically significant corneal or retinal disorders or current evidence of retinal detachment.
  4. Received more than 2 prior FGFRi therapies
  5. Active, symptomatic, or untreated unless the participant is clinically stable and off for ≥2 months.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Phase 1: Dose Escalation

    Multiple doses of CGT4859 for oral administration

    Drug: CGT4859

  • Experimental
    Phase 2: Signal Seeking

    Oral dose of CGT4859 at the RP2D as determined in Phase 1

    Drug: CGT4859

Interventions

  • DrugCGT4859

    CGT4859 is a selective FGFR2/3 inhibitor

06

What researchers measure

Primary outcomes

  1. Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEs

    Incidence, severity, and seriousness or treatment-emergent adverse events (AEs) leading to dose modification

    Time frame: Approximately 12 months

  2. Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - Laboratory results

    Clinically significant changes or abnormalities observed from baseline in laboratory results in chemistry, hematology, and coagulation parameters

    Time frame: Approximately 12 months

  3. Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - ECG results

    Clinically significant changes or abnormalities observed from baseline in electrocardiogram (ECG) parameters

    Time frame: Approximately 12 months

  4. Phase 2: Evaluate antitumor activity of CGT4859 - Objective Response Rate (ORR)

    Time frame: Approximately 8 months

Secondary outcomes

  1. Phase 1: Pharmacokinetics

    Plasma concentration levels of CGT4859

    Time frame: Approximately 28 days

  2. Phase 1: Evaluate antitumor activity of CGT4859 - Objective Response Rate (ORR)

    Time frame: Approximately 8 months

  3. Phase 1 and Phase 2: Evaluate antitumor activity of CGT4859 - Disease Control Rate (DCR)

    Time frame: Approximately 8 months

  4. Phase 2: Characterize the safety of CGT4859 - AEs

    Incidence, severity, and seriousness or treatment-emergent adverse events (AEs) leading to dose modification

    Time frame: Approximately 9 months

  5. Phase 2: Characterize the safety of CGT4859 - Labs, ECG

    Changes from baseline in key laboratory results and electrocardiogram (ECG) parameters

    Time frame: Approximately 9 months

  6. Phase 2: Pharmacokinetics at RP2D

    Plasma concentration levels of CGT4859

    Time frame: Approximately 28 days

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 15, 2025
StartActual
Jan 22, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06777316
Lead sponsor
Cogent Biosciences, Inc.
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Jan 22, 2025
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion